MarketPulse

pharmaceutical

67 articles
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Regeneron's Pipeline Depth and Dupixent Dominance Set Stage for Decade of Growth

Regeneron's Dupixent dominance and deep pipeline across weight management, oncology, and rare diseases position the company for sustained growth through the mid-2030s.
REGNbiotechpatent cliff
The Motley FoolThe Motley Fool··Reuben Gregg Brewer

Pfizer's 6.4% Dividend Yield Attracts Income Investors Despite Sector Headwinds

Pfizer's 6.4% dividend yield attracts income investors, but structural challenges like patent expirations and a payout ratio exceeding 100% present execution risks.
PFEdividend yieldincome investing
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Aquestive to Disclose Q4 2025 Results and Pipeline Progress on March 4-5

Aquestive Therapeutics will report Q4 2025 results March 4 and hold investor call March 5, discussing financial performance and pipeline progress including Anaphylm™ development.
AQSTclinical dataearnings report
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Veeva Systems Eyes $6B Revenue Target Despite Recent Stock Pressure

Veeva Systems targets $6B revenue by 2030, doubling current business. Stock down 35% recently, but specialized platform and customer switching costs support long-term growth outlook.
MRKMSFTGOOGGOOGLLLY+2cloud computingbiotech
BenzingaBenzinga··Vandana Singh

Takeda Stock Falls Despite Positive Pediatric UC Data for Entyvio

Takeda stock fell 0.64% despite positive Phase 3 results for Entyvio in pediatric ulcerative colitis, with 47.3% of patients achieving clinical remission.
TAKPhase 3 trialpharmaceutical
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Nasus Pharma CEO to Present Pipeline at Three Major Healthcare Conferences

Nasus Pharma CEO presents clinical pipeline at three major healthcare conferences in February-March, showcasing NS002 intranasal epinephrine for anaphylaxis treatment.
NSRXclinical-stageinvestor conference
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

AbbVie Stock Declines Despite Strong Quarterly Results and Pipeline Growth

AbbVie stock fell despite strong Q4 results and 10% revenue growth. Investors worry about Humira patent expiration, though new drugs Skyrizi and Rinvoq show promise.
ABBVearnings reportdividend stock